Experimental combo targets Hard-to-Treat gut tumors

NCT ID NCT04234568

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This early-phase trial tests whether adding triapine to standard radioactive therapy (lutetium Lu 177 dotatate) is safe and effective for people with advanced neuroendocrine tumors of the digestive system. About 31 participants whose tumors have worsened after prior treatment will receive the combination. The main goal is to find the best dose and watch for side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC DIGESTIVE SYSTEM NEUROENDOCRINE NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

digestive system neuroendocrine neoplasm digestive system neuroendocrine tumor, grade 1/2 neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC DIGESTIVE SYSTEM NEUROENDOCRINE NEOPLASM METASTATIC NEUROENDOCRINE TUMOR

Contacts and locations

Locations

City of Hope Comprehensive Cancer Center

Duarte, California, 91010, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Huntsman Cancer Institute/University of Utah

Salt Lake City, Utah, 84112, United States
Mayo Clinic Hospital in Arizona

Phoenix, Arizona, 85054, United States
Mayo Clinic in Florida

Jacksonville, Florida, 32224-9980, United States
Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States
Northwestern University

Chicago, Illinois, 60611, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232, United States
University of Kentucky/Markey Cancer Center

Lexington, Kentucky, 40536, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.